KRAS and melanoma: In the cBioPortal database, we found a frequency of 0.5–1.2% samples with CRKL and MAPK1 co-amplification with a trend to mutual exclusivity with KRAS, NRAS and BRAF mutations in NSCLC and melanoma (Fig. S17A-C).